Drug delivery systems provider Aptar Pharma announced that its Bidose nasal spray device was recently approved by the US FDA for depression therapy.
The customised Bidose device is produced in Aptar Pharma’s state-of-the-art manufacturing facility in Congers, NY.
The nasal product platform limits the volume of drug accessible to patients. The devices can also integrate wireless connectivity technologies.
“We are pleased that Aptar Pharma’s Bidose nasal delivery device has been approved by the FDA for this breakthrough therapy in the field of depression,” explained Gael Touya, president of Aptar Pharma.
“This project marks close to a 10-year customer collaboration and once again demonstrates Aptar Pharma’s ability to develop and launch complex drug delivery systems worldwide.”